2024-05-01 12:39:01 ET
Summary
- Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types.
- The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies.
- Immutep should have sufficient funding for 9–10 quarters of research and has demonstrated promising early signals of efficacy and safety.
Topline Summary and Update
Immutep Limited ( IMMP ) is a company I've covered for a few quarters now, with my most recent outing providing a highlight for what I expected would be an exciting 2024. They are focused mainly on developing novel treatments targeting LAG3, an immune checkpoint with a now-established role in the management of melanoma. IMMP is one of the companies trying to push this strategy into other tumor types....
Read the full article on Seeking Alpha
For further details see:
Immutep: Realizing The Expected Catalysts, With More To Come